SCHEMBL7359286

SCHEMBL7359286

N=C(N)c1cccc(O)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.61
PRSS1 P07477 7/20 0.59
F2 P00734 6/20 0.59
PRSS2 P07478 5/20 0.59
PRSS3 P35030 5/20 0.59
PLG P00747 3/20 0.59
C1S P09871 1/20 0.59
F12 P00748 2/20 0.57
LOXL2 Q9Y4K0 1/20 0.55
F10 P00742 1/20 0.54
F7 P08709 1/20 0.54
F3 P13726 1/20 0.54
PKM P14618 1/20 0.54
PLAU P00749 2/20 0.54
KLK1 P06870 2/20 0.54
KLKB1 P03952 1/20 0.54
LMNA P02545 1/20 0.52
BLM P54132 1/20 0.52
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3909792 0.98 PRSS1 (0.63) PARP1PRSS1F2PRSS2PRSS3
SCHEMBL15547311 0.85 PRSS1 (0.70) PRSS1F2PRSS2PRSS3PLG
Trifluoroacetic Acid SCHEMBL3316764 0.84 PARP1 (0.55) PARP1PRSS1F2PRSS2PRSS3
Hydrochloric Acid SCHEMBL28555629 0.82 PRSS1 (0.74) PRSS1F2PRSS2PRSS3PLG
Hydrochloric Acid SCHEMBL28253026 0.82 PRSS1 (0.74) PRSS1F2PRSS2PRSS3PLG
SCHEMBL20937975 0.79 PARP1 (0.53) PARP1PRSS1F2PRSS2PRSS3
SCHEMBL5626124 0.77 PRSS1 (0.75) PRSS1F2PRSS2PRSS3PLG
SCHEMBL31747489 0.76 PARP1 (1.00) PARP1LMNABLMCA12CA1
Hydrochloric Acid SCHEMBL9792863 0.76 PRSS1 (0.83) PRSS1F2PRSS2PRSS3PLG
SCHEMBL14515478 0.76 PARP1 (0.61) PARP1LMNACA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1091955-A1 QUINOLONES AS SERINE PROTEASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2001-04-18 EP claimed
WO-1999050263-A1 QUINOLONES AS SERINE PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 1999-10-07 WO claimed
EP-0703216-B1 Amidinophenol derivatives as protease inhibitors ONO PHARMACEUTICAL CO (JP) 1999-04-07 EP claimed
EP-0656349-B1 Amidinophenol derivatives having phospholipase A2 inhibitory activity ONO PHARMACEUTICAL CO (JP) 1998-04-08 EP claimed
CN-109468659-A The method of room temperature synthesizing benzimidazole under the conditions of electrocatalytic method water phase 云南师范大学 2019-03-15 CN disclosed
CN-109456273-A The method of benzenecarboximidamide class compound synthesis benzimidazole compound is used in microwave method water phase 云南师范大学 2019-03-12 CN disclosed
CN-107108638-A Piperidyl PyrazolopyrimidinonecGMP and application thereof 拜耳制药股份公司 2017-08-29 CN disclosed
WO-2015137408-A1 METHOD FOR PRODUCING HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE, AND PRODUCTION INTERMEDIATE OF SAME 味の素株式会社 2015-09-17 WO disclosed
CN-102993084-B Alkynyl derivatives as modulators of metabotropic glutamate receptors ADDEX PHARMACEUTICALS SA 2015-05-20 CN disclosed
WO-2008072850-A1 TRIAZINE DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST ACETYL-COA CARBOXYLASE AMOREPACIFIC CORPORATION (KR) 2008-06-19 WO disclosed
US-20070021483-A1 Amidine derivatives for treating amyloidosis NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2007-01-25 US disclosed
EP-0893437-A4 TRYPTASE INHIBITOR AND NOVEL GUANIDINO DERIVATIVES ONO PHARMACEUTICAL CO (JP) 2000-12-27 EP disclosed
EP-0703216-B1 Amidinophenol derivatives as protease inhibitors ONO PHARMACEUTICAL CO (JP) 1999-04-07 EP disclosed
WO-1997037969-A1 TRYPTASE INHIBITOR AND NOVEL GUANIDINO DERIVATIVES ONO PHARMACEUTICAL CO., LTD. (JP) 1997-10-16 WO disclosed
EP-0703216-A1 Amidinophenol derivatives as protease inhibitors ONO PHARMACEUTICAL CO., LTD. (JP) 1996-03-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021483-A1 Amidine derivatives for treating amyloidosis APP, IAPP, GRN PARP1 2936/4885PRSS1 2062/4885F2 3712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.